Hepatitis B

Efficacy and safety of xalnesiran in combination with the checkpoint inhibitor PD-L1 LNA in virologically suppressed participants with chronic hepatitis B: results from the Piranga phase 2, randomized, controlled, adaptive, open-label platform study

This poster reports on the primary and secondary endpoint results of the combinations of xalnesiran plus PD-L1 LNA in the Piranga phase 2 platform trial for chronic HBV.

A novel mechanistic viral dynamics modeling (MVDM) framework to characterize and predict the effect of combination therapies in chronic hepatitis B: modeling of the Piranga phase 2, randomized, controlled, adaptive, open-label platform study

Description of a mechanistic model developed to describe the data from Piganga phase 2 platform and understand the effect of each compound on the time course of the different biomarkers. Utilization of the model to simulate different treatment combination strategies.

Outcomes of nucleos(t)ide analogue discontinuation following finite xalnesiran-based therapy in chronic hepatitis B: 48 week follow-up results from Piranga, a phase 2, randomized, controlled, adaptive, open-label platform study

This poster reports the NA discontinuation events, and the efficacy and safety outcomes of participants in the 4 xalnesiran-based arms from the Piranga phase 2 study.

Pharmacokinetic/pharmacodynamic modelling of RG6084 effects on hepatitis B surface antigen and alanine transaminase to inform Phase 2 dosing regimen selection

Description of the PK/PD models that were developed using the phase 1 data together with simulations of expected effect for different dose levels supporting the phase 2 dose rational.

Liver-directed Targeting of PD-L1 with RO7191863, a Locked Nucleic Acid, in Chronic Hepatitis B: First Report of Phase 1 Tolerability, Pharmacokinetics, and Pharmacodynamics

Roche Combination Therapy Approach For Functional Cure

External site

Hepatitis B

Ask a question or share feedback